Mirati Therapeutics, Inc.: Cracking KRAS Is Harder Than It Looks Seeking Alpha, 21 Apr 2020 We are short shares of Mirati Therapeutics, a $4.6bn clinical-stage biopharmaceutical company whose lead drug candidate, MRTX-849…